Press Releases

Replimune Group Inc. , a biotechnology company developing oncolytic immuno-gene therapies derived from its Immulytic platform, announced that the first patient has been enrolled in its registration-directed, randomized, controlled Phase 2 clinical trial of RP1 in combination with Regeneron...

Alexion Pharmaceuticals, Inc. and Stealth BioTherapeutics Corp announced an agreement for an option to co-develop and commercialize elamipretide for mitochondrial diseases. Currently being evaluated in a Phase 3 study in people with primary mitochondrial myopathy (PMM) - a genetic...

Bayer AG and its development partner Janssen Research & Development, LLC announced that the U.S. FDA has approved rivaroxaban (Xarelto) for the prevention of venous thromboembolism (VTE), or blood clots, in acutely ill medical patients at risk for thromboembolic...

At the upcoming CPhI Worldwide in Frankfurt (Germany), Romaco and Huhtamaki will show the first recyclable strip packaging for pharmaceutical solids. An HM 1-230 heat-sealing machine from Romaco Siebler will be used to manufacture the Push Packs. Pharmaceutical manufacturer Romaco...

Akcea Therapeutics, Inc. , a majority-owned affiliate of Ionis Pharmaceuticals, Inc. and Pfizer Inc. , announced that the companies have entered into a worldwide exclusive licensing agreement for AKCEA-ANGPTL3-LRx, an investigational antisense therapy being developed to treat patients with...

GlaxoSmithKline plc  announced a five-year collaboration with Lyell Immunopharma, a San Francisco biotechnology company, to develop new technologies to improve cell therapies for cancer patients. The collaboration will apply Lyell’s technologies to further strengthen GSK’s cell therapy pipeline, including...

The National Institute for Health Research Bristol Biomedical Research Centre (NIHR Bristol BRC) at the University of Bristol has selected Signant Health, formerly CRF Health and Bracket, as its partner to provide electronic informed consent (eConsent) support for an...